Cellular senescence is a state in which cells permanently stop dividing (cell cycle arrest) but do not die. It is triggered by severe DNA damage, telomere shortening, oncogenic stress, or oxidative damage — it is an evolved cancer-prevention mechanism (a potentially pre-cancerous cell that won't divide cannot form a tumor). The problem: senescent cells are supposed to be cleared by the immune system (NK cells, macrophages) and replaced. This works well in youth. With aging, two things fail: (1) senescent cells accumulate faster than clearance can handle; (2) the immune system becomes less effective at recognizing and eliminating them (a component of immune aging / inflammaging). The result is a progressive accumulation of "zombie cells" — alive but dysfunctional, secreting the SASP indefinitely.
The SASP (senescence-associated secretory phenotype) is the mechanism of damage: a cocktail of pro-inflammatory cytokines (IL-6, IL-8, IL-1β), matrix metalloproteinases (MMPs that degrade the extracellular matrix), reactive oxygen species, and senescence-inducing signals that can force neighboring healthy cells into senescence (a bystander effect). The SASP links cellular senescence to virtually every major age-related disease: atherosclerosis, type 2 diabetes, osteoporosis, neurodegeneration, and cancer (paradoxically — the SASP creates a pro-tumor microenvironment even as the senescent cell itself cannot divide).
| Agent | Mechanism | Animal Evidence | Human Evidence | Status |
|---|---|---|---|---|
| Quercetin + Dasatinib (Q+D) | Dasatinib (BCR-ABL inhibitor) targets SRC kinase and BCL-2/BCL-xL survival pathways in senescent cells. Quercetin inhibits PI3K, serpin B2, and additional senescent-cell survival pathways. Together they overcome the anti-apoptotic defenses that allow senescent cells to resist programmed death. | Zhu 2015 (Aging Cell): Q+D reduced senescent cells in multiple tissues, improved physical function, extended healthspan in aged mice; Baker 2011 INK-ATTAC model foundational | Justice 2019 (EBioMedicine, N=9): first human proof-of-concept; 28% reduction p16 in adipose, 30% p21, reduced circulating IL-6 and MMP-9; Kirkland's group ongoing Phase 2 trials in multiple conditions (pulmonary fibrosis, osteoporosis, Alzheimer's) | Dasatinib is a prescription chemotherapy drug (FDA-approved for leukemia) — not available OTC; off-label use requires physician oversight; human trial evidence is early but mechanism-sound |
| Fisetin | Fisetin is a flavonoid (found in strawberries, apples, onions) that inhibits PI3K/mTOR and MDM2 survival pathways in senescent cells; promotes apoptosis of senescent but not normal cells; also has mTOR inhibition and anti-inflammatory properties beyond senolytics per se | Kirkland 2019 (EBioMedicine): fisetin 500ppm chow extended remaining lifespan 10% in aged mice; reduced senescence markers 25–50%; improved multiple healthspan measures; Yousefzadeh 2018 (EBioMedicine): fisetin had highest senolytic activity of 10 flavonoids tested | No published human senolytic RCT yet as of June 2026; Kirkland group has AFFIRM-LITE trial underway (NCT04210986): fisetin 20mg/kg/day × 2 days in older frail adults; results anticipated 2026–2027; substantial human fisetin safety data from cancer chemoprevention trials at lower doses | Available as supplement; most promising OTC senolytic based on mouse data; human evidence pending; dosing for senolytic effect (20mg/kg) far exceeds typical supplement doses (100–500mg) |
| Navitoclax (ABT-263) | BCL-2/BCL-xL/BCL-W inhibitor; directly induces apoptosis in senescent cells that depend on BCL-2 family proteins for survival; highly potent senolytic | Chang 2016 (Nature Medicine): navitoclax restored hematopoietic stem cell function in aged mice; Zhu 2016: cleared pulmonary senescent cells; potent senolytic in multiple models | No human longevity trials; used in oncology trials (thrombocytopenia side effect limits dose); mechanistically informative for understanding BCL-2 dependence of senescent cells | Not available as supplement; oncology drug with significant toxicity at senolytic doses; informs senolytic biology but not a practical human intervention currently |
| Piperlongumine | Natural compound from long pepper that selectively kills senescent cells by increasing reactive oxygen species beyond the threshold senescent cells can tolerate (senescent cells have elevated baseline ROS and are closer to oxidative death threshold) | Wang 2016 (Oncotarget): piperlongumine cleared senescent cells and reduced SASP in vitro and in mouse models; improved wound healing | No human senolytic trials; safety profile not established at senolytic doses in humans | Research stage only; interesting mechanism but limited data and no human evidence |
The senescence-associated secretory phenotype (SASP) is the reason senescent cell accumulation matters. A single senescent cell is not a problem. Billions of them, distributed across every tissue in an aging body, secreting IL-6 (a pro-inflammatory cytokine that drives systemic inflammation), IL-8 (a neutrophil chemoattractant), MMP-2 and MMP-9 (proteases that degrade collagen, elastin, and the extracellular matrix — driving tissue aging), and TGF-β (a fibrosis signal) — this creates the chronic, low-grade inflammatory state called "inflammaging" that is the common root of virtually all age-related chronic diseases. Fabbri 2021: circulating SASP factors (measured as p16INK4a expression in peripheral blood T cells) predicted mortality and morbidity in the UK Biobank cohort (N=4,000+) better than chronological age. The SASP also creates immune dysfunction through NK cell exhaustion (senescent cells gradually overwhelm the immune senolytic capacity) and through secretion of immune checkpoint ligands that disable T cells — a mechanism that overlaps with tumor immune evasion.
The mouse senolytic data is among the most compelling in longevity biology — the Baker 2011 experiment (genetic elimination of senescent cells) is a landmark result. However, the translation gap is significant and honest practitioners must acknowledge it. Mice and humans differ in key ways: mouse lifespan is 2–3 years (interventions can be tested on decades-equivalent timescales); mouse senescent cell biology may differ in proportion and tissue distribution from humans; the doses of fisetin used in mice (20mg/kg/day × 2 days = 1,400mg for a 70kg person) are substantially higher than typical supplement doses (100–500mg); and dasatinib has a toxicity profile that complicates its use for healthy aging prevention. The first human senolytics studies (Justice 2019 and subsequent Mayo Clinic trials) are showing biologically plausible results — reduced senescence markers in tissues — but have small sample sizes and no long-term human healthspan outcomes yet. This is a promising area, not a proven one.
Lifestyle foundations come first: Exercise (particularly high-intensity interval training) has been shown to reduce senescent cell burden and SASP markers in humans (Schafer 2016); caloric restriction reduces senescent cell accumulation; adequate sleep (glymphatic clearance) and smoking cessation dramatically reduce senescent cell burden. These lifestyle factors have far stronger human evidence than any pharmacological senolytic and should be the foundation before considering supplements.
Fisetin — the most practical OTC option based on mouse evidence: The mouse dose translating to humans is approximately 20mg/kg/day × 2 days (a "pulsed" dosing strategy, not daily supplementation). For a 70kg adult: ~1,400mg/day × 2 days on, then off for 4–8 weeks, then repeat. Most OTC fisetin supplements are 100–500mg — achieving senolytic doses requires multiple capsules or a high-dose formulation. Important: this dose has not been validated in human senolytic RCTs; the AFFIRM-LITE trial results will be the first human evidence at this dose level. Fisetin has a good safety profile at lower doses from cancer chemoprevention research. Bioavailability is low — take with fat and do not combine with mTOR inhibitors without physician oversight.
Quercetin — as a standalone (without Dasatinib): Quercetin alone (without dasatinib) has weaker senolytic activity than the combination; the Q+D human evidence used both together; quercetin alone at 500–1,000mg/day has senomorphic (SASP-suppressing) effects even if not fully senolytic; quercetin phytosome (Quercefit) has 20x higher bioavailability than standard quercetin. Quercetin 500mg + fisetin at the higher doses may have additive effects.
Monitoring — when to assess: No validated consumer biomarker for senescent cell burden exists as of mid-2026. Circulating p16INK4a expression in peripheral blood T cells (measured in research settings) correlates with tissue senescent cell burden; some longevity clinics offer this. Proxy markers: hsCRP (systemic inflammation), IL-6, MMP-9 — reducing these via lifestyle interventions, then retesting after a senolytic protocol, provides indirect evidence of efficacy.
As an Amazon Associate, LongevityLab earns from qualifying purchases made through links on this page. This does not affect the price you pay.